

Veronika J Wirtz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2808548/publications.pdf>

Version: 2024-02-01

112
papers

2,905
citations

236925

25
h-index

197818

49
g-index

122
all docs

122
docs citations

122
times ranked

4233
citing authors

#	ARTICLE	IF	CITATIONS
1	Essential medicines for universal health coverage. <i>Lancet, The</i> , 2017, 389, 403-476.	13.7	366
2	Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. <i>Lancet, The</i> , 2013, 381, 680-689.	13.7	190
3	Estimating the Burden of Chagas Disease in the United States. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005033.	3.0	174
4	COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. <i>The Lancet Global Health</i> , 2020, 8, e754-e755.	6.3	128
5	Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries. <i>Circulation</i> , 2016, 133, 2076-2085.	1.6	122
6	How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 307-321.	2.1	111
7	Policies to promote use of generic medicines in low and middle income countries: A review of published literature, 2000â€“2010. <i>Health Policy</i> , 2012, 106, 211-224.	3.0	99
8	Trends in antibiotic utilization in eight Latin American countries, 1997-2007. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2010, 27, 219-25.	1.1	99
9	Impact of Over-the-Counter Restrictions on Antibiotic Consumption in Brazil and Mexico. <i>PLoS ONE</i> , 2013, 8, e75550.	2.5	98
10	Access to Care for Chagas Disease in the United States: A Health Systems Analysis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 108-113.	1.4	94
11	The costs of diabetes treatment in low- and middle-income countries: a systematic review. <i>BMJ Global Health</i> , 2019, 4, e001258.	4.7	88
12	Heterogeneous Effects of Health Insurance on Out-of-Pocket Expenditure on Medicines in Mexico. <i>Value in Health</i> , 2012, 15, 593-603.	0.3	55
13	Analysing policy interventions to prohibit overâ€“theâ€“counter antibiotic sales in four Latin American countries. <i>Tropical Medicine and International Health</i> , 2013, 18, 665-673.	2.3	53
14	Evaluating the Implementation of Mexico's Health Reform: The Case of <i>Seguro Popular</i> . <i>Health Systems and Reform</i> , 2015, 1, 217-228.	1.2	51
15	Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV. <i>Pharmacoeconomics</i> , 2011, 29, 579-599.	3.3	50
16	The Market Dynamics of Generic Medicines in the Private Sector of 19 Low and Middle Income Countries between 2001 and 2011: A Descriptive Time Series Analysis. <i>PLoS ONE</i> , 2013, 8, e74399.	2.5	44
17	Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial. <i>The Lancet Global Health</i> , 2019, 7, e492-e502.	6.3	38
18	Regulation of antibiotic sales in Mexico: an analysis of printed media coverage and stakeholder participation. <i>BMC Public Health</i> , 2012, 12, 1051.	2.9	37

#	ARTICLE	IF	CITATIONS
19	International short-term medical missions: a systematic review of recommended practices. <i>International Journal of Public Health</i> , 2017, 62, 31-42.	2.3	34
20	Veterinary antimicrobial resistance containment in Bangladesh: Evaluating the national action plan and scoping the evidence on implementation. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 105-115.	2.2	33
21	Global access to quality-assured medical products: the Oxford Statement and call to action. <i>The Lancet Global Health</i> , 2019, 7, e1609-e1611.	6.3	32
22	Seasonal Variation in Penicillin Use in Mexico and Brazil: Analysis of the Impact of Over-the-Counter Restrictions. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 105-110.	3.2	30
23	Essential medicines are still essential. <i>Lancet, The</i> , 2015, 386, 1601-1603.	13.7	29
24	Obstetric Care and Method of Delivery in Mexico: Results from the 2012 National Health and Nutrition Survey. <i>PLoS ONE</i> , 2014, 9, e104166.	2.5	28
25	Health facility and skilled birth deliveries among poor women with Jamkesmas health insurance in Indonesia: a mixed-methods study. <i>BMC Health Services Research</i> , 2017, 17, 105.	2.2	28
26	Challenges of medicines management in the public and private sector under Ghana's National Health Insurance Scheme – A qualitative study. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 6.	2.4	26
27	A new entity for the negotiation of public procurement prices for patented medicines in Mexico. <i>Bulletin of the World Health Organization</i> , 2012, 90, 788-792.	3.3	25
28	Effects of the expansion of doctors' offices adjacent to private pharmacies in Mexico: secondary data analysis of a national survey. <i>BMJ Open</i> , 2014, 4, e004669.	1.9	24
29	Incremental Risk of Developing Severe COVID-19 Among Mexican Patients With Diabetes Attributed to Social and Health Care Access Disadvantages. <i>Diabetes Care</i> , 2021, 44, 373-380.	8.6	23
30	Factors influencing global antiretroviral procurement prices. <i>BMC Public Health</i> , 2009, 9, S6.	2.9	22
31	Availability and prices of medicines for non-communicable diseases at health facilities and retail drug outlets in Kenya: a cross-sectional survey in eight counties. <i>BMJ Open</i> , 2020, 10, e035132.	1.9	21
32	Geographical accessibility of medicines: a systematic literature review of pharmacy mapping. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 28.	2.4	21
33	Perceptions of Kenyan adults on access to medicines for non-communicable diseases: A qualitative study. <i>PLoS ONE</i> , 2018, 13, e0201917.	2.5	20
34	A perspective on global access to insulin: a descriptive study of the market, trade flows and prices. <i>Diabetic Medicine</i> , 2019, 36, 726-733.	2.3	20
35	Access to Medicines by Seguro Popular Beneficiaries: Pending Tasks towards Universal Health Coverage. <i>PLoS ONE</i> , 2015, 10, e0136823.	2.5	20
36	Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence. <i>Health Affairs</i> , 2017, 36, 706-713.	5.2	19

#	ARTICLE	IF	CITATIONS
37	The prevalence and correlates of severe depression in a cohort of Mexican teachers. <i>Journal of Affective Disorders</i> , 2018, 234, 109-116.	4.1	19
38	Financing HIV Programming: How Much Should Low- And Middle-Income Countries and their Donors Pay?. <i>PLoS ONE</i> , 2013, 8, e67565.	2.5	19
39	Medicines in Mexico, 1990-2004: systematic review of research on access and use. <i>Salud Publica De Mexico</i> , 2008, 50, S470-S479.	0.4	17
40	Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 9.	2.4	16
41	Access to medicines for asthma, diabetes and hypertension in eight counties of Kenya. <i>Tropical Medicine and International Health</i> , 2018, 23, 879-885.	2.3	16
42	Consumption of systemic antibiotics in India in 2019. , 2022, 4, 100025.		15
43	Organizational elements of health service related to a reduction in maternal mortality: The cases of Chile and Colombia. <i>Health Policy</i> , 2009, 90, 149-155.	3.0	14
44	Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review. <i>Globalization and Health</i> , 2019, 15, 88.	4.9	14
45	Reforming antiretroviral price negotiations and public procurement: the Mexican experience. <i>Health Policy and Planning</i> , 2013, 28, 1-10.	2.7	13
46	Study protocol for a cluster-randomised controlled trial of an NCD access to medicines initiative: evaluation of Novartis Access in Kenya. <i>BMJ Open</i> , 2016, 6, e013386.	1.9	13
47	Pharmacy customers' knowledge of side effects of purchased medicines in Mexico. <i>Tropical Medicine and International Health</i> , 2009, 14, 93-100.	2.3	12
48	Ambulatory health service users' experience of waiting time and expenditure and factors associated with the perception of low quality of care in Mexico. <i>BMC Health Services Research</i> , 2010, 10, 178.	2.2	12
49	Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America. <i>Health Policy and Planning</i> , 2012, 27, 638-648.	2.7	11
50	Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009. <i>Tropical Medicine and International Health</i> , 2013, 18, 416-425.	2.3	11
51	Essential medicines for universal health coverage " Authors' reply. <i>Lancet, The</i> , 2017, 389, 1881-1882.	13.7	11
52	The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists. <i>BMJ Global Health</i> , 2019, 4, e001681.	4.7	11
53	Hospitalisation and mortality from COVID-19 in Mexican indigenous people: a cross-sectional observational study. <i>Journal of Epidemiology and Community Health</i> , 2022, 76, 16-23.	3.7	11
54	Access to asthma medicines at the household level in eight counties of Kenya. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 585-590.	1.2	10

#	ARTICLE	IF	CITATIONS
55	Equity in access to non-communicable disease medicines: a cross-sectional study in Kenya. <i>BMJ Global Health</i> , 2018, 3, e000828.	4.7	10
56	Barriers to Accessing Medicines among Syrian Asylum Seekers and Refugees in a German Federal State. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 519.	2.6	10
57	Oseltamivir storage, distribution and dispensing following the 2009 H1N1 influenza outbreak in Mexico. <i>Bulletin of the World Health Organization</i> , 2012, 90, 782-787.	3.3	9
58	Indicators of quality use of medicines in South and East Asian countries: a systematic review. <i>Tropical Medicine and International Health</i> , 2012, 17, 1552-1566.	2.3	9
59	Antenatal Care Among Poor Women in Mexico in the Context of Universal Health Coverage. <i>Maternal and Child Health Journal</i> , 2015, 19, 2314-2322.	1.5	9
60	A global accountability mechanism for access to essential medicines. <i>Lancet, The</i> , 2018, 392, 2418-2420.	13.7	9
61	Bacterial antibiotic resistance development and mutagenesis following exposure to subminimal inhibitory concentrations of fluoroquinolones in vitro: a systematic literature review protocol. <i>BMJ Open</i> , 2019, 9, e030747.	1.9	9
62	Outpatient Antibiotic Dispensing for the Population with Government Health Insurance in Syria in 2018 and 2019. <i>Antibiotics</i> , 2020, 9, 570.	3.7	9
63	How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics?. <i>Journal of Medical Economics</i> , 2016, 19, 881-888.	2.1	8
64	Beyond availability and affordability: how access to medicines affects non-communicable disease outcomes. <i>Lancet Public Health, The</i> , 2017, 2, e390-e391.	10.0	8
65	Comparison of medicines management strategies in insurance schemes in middle-income countries: four case studies. <i>Journal of Pharmaceutical Policy and Practice</i> , 2017, 10, 17.	2.4	8
66	Monetary and nonmonetary household consumption of health services and the role of insurance benefits: An analysis of the Mexico's National Household Income and Expenditure Survey. <i>International Journal of Health Planning and Management</i> , 2018, 33, 847-859.	1.7	8
67	Regional and state-level patterns of type 2 diabetes prevalence in Mexico over the last three decades. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108927.	2.8	8
68	Effects of over-the-counter sales restriction of antibiotics on substitution with medicines for symptoms relief of cold in Mexico and Brazil: time series analysis. <i>Health Policy and Planning</i> , 2016, 31, 1291-1296.	2.7	7
69	Operational rules for the implementation of INN prescribing. <i>International Journal of Medical Informatics</i> , 2014, 83, 47-56.	3.3	6
70	Commitment to Impact: Strengthening Measurement of Industry-Led Access-to-Medicines Programs. <i>Health Systems and Reform</i> , 2018, 4, 188-193.	1.2	6
71	Evaluation of the effects of a generic substitution policy implemented in Chile. <i>BMJ Global Health</i> , 2019, 2, e000922.	4.7	6
72	Predictors of health facility readiness for diabetes service delivery in low- and middle-income countries: The case of Bangladesh. <i>Diabetes Research and Clinical Practice</i> , 2020, 169, 108417.	2.8	6

#	ARTICLE	IF	CITATIONS
73	Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones in vitro: a systematic review of the literature. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa068.	2.1	6
74	Public health insurance and ethnic disparities in maternal health care: the case of vulnerable Mexican women over the last 25 years. <i>Health Policy and Planning</i> , 2021, 36, 1671-1680.	2.7	6
75	Optimizing HIV treatment programs. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 232-236.	3.8	5
76	Access to medicines among internally displaced and non-displaced people in urban areas in Colombia. <i>Cadernos De Saude Publica</i> , 2012, 28, 2245-2256.	1.0	5
77	A research agenda to promote affordable and quality assured medicines. <i>Journal of Pharmaceutical Policy and Practice</i> , 2014, 7, 2.	2.4	5
78	Access to Antihypertensive Medicines at the Household Level. , 2018, 13, 247-253.e5.		5
79	The implementation of pharmaceutical services in public hospitals in Mexico: an analysis of the legal framework and organizational practice. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 41.	2.4	5
80	Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 18.	2.4	5
81	Probability and amount of medicines expenditure according to health insurance status in Kenya: A household survey in eight counties. <i>International Journal of Health Planning and Management</i> , 2021, , .	1.7	5
82	Comparative analysis of essential medicines for cardiovascular diseases in countries of the WHO Eastern Mediterranean Region. <i>Eastern Mediterranean Health Journal</i> , 2018, 24, 427-434.	0.8	5
83	Access to Medicines for Non-Communicable Diseases (NCDs) during COVID-19 in Kenya: A Descriptive Commentary. <i>Health Systems and Reform</i> , 2021, 7, e1984865.	1.2	5
84	Strategies and ethical considerations for the recruitment of young men who have sex with men: challenges of a vaccination trial in Mexico. <i>Clinical Trials</i> , 2009, 6, 365-372.	1.6	4
85	Increasing Access to Treatment for Chagas Disease: The Case of Morelos, Mexico. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 1125-1127.	1.4	4
86	Impact of the introduction of mandatory generic substitution in South Africa: private sector sales of generic and originator medicines for chronic diseases. <i>Tropical Medicine and International Health</i> , 2016, 21, 1504-1512.	2.3	4
87	Coping with access barriers to non-communicable disease medicines: qualitative patient interviews in eight counties in Kenya. <i>BMC Health Services Research</i> , 2021, 21, 417.	2.2	4
88	Access to medicines by ambulatory health service users in Mexico: an analysis of the national health surveys 1994 to 2006. <i>Salud Publica De Mexico</i> , 2010, 52, 30-38.	0.4	4
89	Evaluating the quality and use of economic data in decisions about essential medicines. <i>Bulletin of the World Health Organization</i> , 2015, 93, 693-699.	3.3	4
90	Household access to non-communicable disease medicines during universal health care roll-out in Kenya: A time series analysis. <i>PLoS ONE</i> , 2022, 17, e0266715.	2.5	4

#	ARTICLE	IF	CITATIONS
91	The Effects of Trade Agreements on Imports of Biologics: Evidence from Chile. <i>Journal of Globalization and Development</i> , 2020, 10, .	0.3	3
92	Phone-based monitoring to evaluate health policy and program implementation in Kenya. <i>Health Policy and Planning</i> , 2021, 36, 444-453.	2.7	3
93	Essential medicines for universal health coverage. <i>Kazan Medical Journal</i> , 2019, 100, 4-111.	0.2	3
94	Outpatient cardiovascular diseases and diabetes medicines dispensing in the population with government health insurance in Syria between 2018 and 2019: a retrospective analysis. <i>BMC Health Services Research</i> , 2021, 21, 1088.	2.2	3
95	Challenges of Guaranteeing Access to Medicines in Mexico: Lessons from Recent Changes in Pharmaceuticals Procurement. <i>Health Systems and Reform</i> , 2022, 8, .	1.2	3
96	The implementation of the bioequivalence certification policy in Chile: An analysis of market authorization data. <i>PLoS ONE</i> , 2019, 14, e0217334.	2.5	2
97	Evaluation of pharmaceutical industry-led access programmes: a standardised framework. <i>BMJ Global Health</i> , 2019, 4, e001659.	4.7	2
98	Benchmarking national action plans on antimicrobial resistance in eight selected LMICs: Focus on the veterinary sector strategies. <i>Journal of Global Health</i> , 2020, 10, 020414.	2.7	2
99	Cross-sectional survey to describe medicine use among Syrian asylum seekers and refugees in a German federal state: looking beyond infectious diseases. <i>BMJ Open</i> , 2021, 11, e053044.	1.9	2
100	Mission Hospital Responses to Challenges and Implications for their Future Role in Indiaâ€™s Health System. <i>Christian Journal for Global Health</i> , 2020, 7, 19-36.	0.1	2
101	Improving access to treatment for HIV in sub-Saharan Africa. <i>BMJ: British Medical Journal</i> , 2010, 341, c6546-c6546.	2.3	1
102	Measuring universities' commitments to global health. <i>Lancet, The</i> , 2013, 382, 204-205.	13.7	1
103	Reply to "Decrease in Penicillin Sales in Brazil after Over-the-Counter Restrictions". <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5864-5864.	3.2	1
104	Response by Wirtz et al to Letter Regarding Article, "Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries". <i>Circulation</i> , 2016, 134, e305-e306.	1.6	1
105	Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation checklist. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 5.	2.4	1
106	Diabetes mellitus as a risk factor for SARS-CoV-2 test positivity in Mexico: A propensity score matched study. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108953.	2.8	1
107	Promoting Access to Cancer Medicines in Mexico: Seguro Popular Key Policy Components. , 2020, , 177-222.		1
108	The Social Costs of Success: The Impact of World Trade Organization Rules on Insulin Prices in Bangladesh upon Graduation from Least Developed Country Status. <i>Asian Development Review</i> , 2022, 39, 239-279.	1.5	1

#	ARTICLE	IF	CITATIONS
109	Policy Space for Building Production Capabilities in the Pharmaceuticals Sector in Low- and Middle-Income Countries: Evidence from Bangladesh. <i>Journal of Globalization and Development</i> , 2022, 12, 221-261.	0.3	1
110	Commercial and Social Value of Pharmaceutical Industry-led Access Programs: Conceptual Framework and Descriptive Analysis. <i>Health Systems and Reform</i> , 2022, 8, e2057831.	1.2	1
111	Registration timelines of antiretroviral medicines in Ghana and Kenya. <i>Aids</i> , 2020, 34, 1093-1095.	2.2	0
112	OUP accepted manuscript. <i>International Journal of Pharmacy Practice</i> , 2022, , .	0.6	0